THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

11 July 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

£1.0 million subscription by major shareholders to accelerate AI drug discovery programme

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, announces that it has raised gross proceeds of £1.0 million through a direct subscription (the "Subscription") for 333,333,334 new ordinary shares of £0.001 each in the capital of the Company (the "Subscription Shares") at a price of 0.3 pence per Subscription Share (the "Issue Price"). The Issue Price is approximately a 3.5% premium to the closing price of 0.29 pence per share on 10 July 2025.

The Subscription is being undertaken by three of the Company's largest shareholders, reflecting their continued strong support for Solvonis' strategy and execution.

Use of proceeds

The net proceeds of the Subscription will be deployed to accelerate Solvonis' AI supported central nervous system drug discovery programme, which is initially focused on major depressive disorder and stimulant use disorder, being two therapeutic areas with significant unmet needs and limited innovation. The global antidepressant drug market was valued by Global Market Insights, the global market research and management consulting company catering to corporations, non-profits, universities, and government agencies, at approximately £15 billion in 2024. Global Market Insights projects this to grow at a compound annual growth rate of 7.5% through to 2034. Meanwhile, stimulant use disorders, such as those related to cocaine and amphetamine dependence, remain underserved by the pharmaceutical industry, with no FDA-approved medications currently available, despite the substantial public health burden they represent (source: U.S. Veterans Affairs Health Services R&D).

Solvonis is uniquely positioned to address both of these high-burden conditions through its AI enabled, central nervous system focused R&D platform. This R&D platform integrates proprietary compound libraries, predictive modelling and rapid translational tools to drive discovery in areas traditionally marked by low investment and slow innovation.

The proceeds from the Subscription will enable the Company to accelerate lead identification and early-stage candidate validation across these two core therapeutic indications.

Admission and Total Voting Rights

Application will be made for the Subscription Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission").

It is expected that Admission will become effective and that dealings in the Subscription Shares will commence at 8.00 a.m. on or around 17 July 2025.

Following Admission, the Company's enlarged issued ordinary share capital will comprise 6,242,104,024 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "We are pleased to receive this investment from our largest and longest-standing shareholders. Their continued conviction supports our strategy to lead innovation in addiction and mental health therapeutics, including the acceleration of our proprietary AI-supported discovery platform. This funding enables acceleration of building a differentiated pipeline in stimulant use and depressive disorders."

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

The Company's lead programmes address Alcohol Use Disorder ("AUD") and Post-Traumatic Stress Disorder ("PTSD"), conditions which the Company estimates affect over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK and EU. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery programme built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.